Tislelizumab for advanced esophageal squamous cell carcinoma
1. Median overall survival was 17.2 months in the tislelizumab group versus 10.6 months in the placebo group (HR 0.66). ...
Tag: esophageal cancer
Addition of PD-L1 inhibitor may improve outcomes in neoadjuvant therapy for esophageal cancer
1. In this phase II randomized clinical trial, treatment of patients with locally advanced esophageal squamous cell carcinoma (ESCC) with ...
#StudyGraphics: Gastric bypass surgery may reduce the risk of esophagogastric cancer in patients with obesity
Click to read this study in JAMA Surgery.
#VisualAbstract: Tislelizumab significantly improves survival outcomes in advanced or metastatic esophageal squamous cell carcinoma
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: FOLFOX in combination with nivolumab and trastuzumab improves survival in metastatic ERBB2⁺ esophagogastric adenocarcinoma
Click to read this study in JAMA Oncology.
#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression
Click to read this study in The Lancet Oncology.
#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer
Click to read this study in The Lancet Oncology.
#VisualAbstract: No difference in survival between fluorouracil, cisplatin, or carboplatin-based paclitaxel therapy for locally advanced esophageal squamous cell carcinoma
Click to read this study in JAMA Network Open.
Nivolumab combination therapies improved overall survival in patients with advanced esophageal squamous cell carcinoma
1. Nivolumab in combination with chemotherapy or ipilimumab significantly prolonged overall survival compared to chemotherapy alone. 2. Common treatment-related adverse ...
#VisualAbstract: Taxane monotherapy may be more effective for patients with recurrent or metastatic head and neck cancer and prior nivolumab exposure
Click to read this study in the European Journal of Cancer.